An analyst sees massive upside after the Novo Nordisk deal.

Novo Nordisk to support Veru’s Phase 2b PLATEAU trial evaluating enobosarm in combination with Novo Nordisk’s obesity drug Wegovy in older adults receiving Wegovy for weight reduction. Veru will ...

Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.

Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming ...

There were no increases in gastrointestinal side effects. There is also no evidence of drug-induced liver injury, or increases in obstructive sleep apnea at any dose of enobosarm compared to the ...

Veru Inc. (NASDAQ:VERU) stock is plummeting on Monday after the company released topline results from the Phase 2b QUALITY clinical study of enobosarm for weight reduction. The study evaluates the ...

--International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced Breast Cancer-- --Preclinical Studies Support Enobosarm’s Novel Mechanism of Action as an AR ...

Veru agreed to conduct a clinical study of one of its treatments in combination with Novo Nordisk's Wegovy weight loss drug. Under the terms of a supply agreement with Novo, Veru will conduct and ...

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced results of its two Phase 3 enobosarm clinical trials, the POWER trials, in patients with non-small cell lung cancer (NSCLC) ...

Credit: Getty Images. Enobosarm is an oral, first-in-class, selective androgen receptor agonist. The Food and Drug Administration (FDA) has granted Fast Track designation to enobosarm for the ...

Enobosarm (GTx-024) is a selective androgen receptor modulator (SARM), a new class of non-steroidal, tissue-specific anabolic agents that has the potential to increase muscle mass and improve physical ...

MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (NAS: GTXI) today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition ...